🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our CEO, Chris Viehbacher, is sharing Biogen’s strategy and key growth drivers at the 43rd Annual J.P. Morgan Healthcare Conference. Join the webcast live on January 14, at 9:45am PT/12:45pm ET. Register here: ow.ly/1Qr850UFyqf

#News: With Eisai, we announced the completion of the filing submission with the U.S. Food and Drug Administration for our Alzheimer’s treatment. Learn more about this milestone: bit.ly/3PyHRIL

Biogen will report Q4 and full year 2024 financial results on February 12 before markets open in the U.S. Learn more: ow.ly/8rha50UL9wz #Earnings $BIIB

#News: The U.S. Food and Drug Administration and the European Medicines Agency have accepted our marketing applications for an investigational form of a spinal muscular atrophy therapy. Learn more: bit.ly/4hqBQKi

#News: With Eisai, the U.S. Food and Drug Administration has approved a maintenance dose for people living with #AlzheimersDisease. Learn more about this milestone: ow.ly/7bTv50UNKtk

STARTING SOON: Join our Q4 and full year 2024 financial results live webcast at 8:30 AM ET. Join here: ow.ly/v5vV50UY8Lb #Earnings $BIIB

This morning, we reported our Q4 and full year 2024 financial results. Watch the full recording here: ow.ly/ol9R50UYCxf #Earnings $BIIB

#News: We are excited to announce a new collaboration with Stoke Therapeutics for a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome. Read the news: bit.ly/430ub1b

#News: We announced the initiation of the Phase 3 study of our investigational therapy for late antibody-mediated rejection (AMR) in kidney transplant patients. Learn more about the news: bit.ly/3XHj1uF

We announced plans for a new global headquarters to open in Kendall Square in 2028 — marking Biogen's 50th anniversary. When open, this state-of-the-art facility will bring our Cambridge teams together at the heart of innovation and biotech.

At #ADPD2025, we’ll be discussing the role of tau in Alzheimer’s disease, including its link to disease progression and neuronal loss. Learn more about tau’s impact and explore interactive resources at KnowTau.com.

#News: Today we announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to one of our investigational drugs for Alzheimer's disease. Learn about this important news: bit.ly/4i8ltlC

#News: Our treatment for early #AlzheimersDisease with Eisai has received EU approval, advancing care options across Europe. Learn more about this milestone and what it may mean for the future of Alzheimer’s care: bit.ly/4lywv6p

#News: Read our Q1 2025 financial results here: ow.ly/69hC50VLcEa #Earnings | $BIIB

STARTING SOON: Join our Q1 2025 financial results live webcast at 8:30 AM ET. Join here: ow.ly/gE3y50VKVnB #Earnings $BIIB

Our Q1 financial results support our strategy for long-term growth. We aim to bring innovative medicines to patients while generating value for our shareholders. Read more: ow.ly/1MG650VLAgP

We’re transforming what’s possible in neurology, immunology, and rare diseases by following promising science and establishing strategic partnerships. See how we’re making important progress in our pipeline to help advance health outcomes.

Collaboration with other industry experts at events like Lupus 2025 provides us with valuable insights to help drive progress for people living with lupus. We look forward to attending #LUPUS2025. Learn about our work: ow.ly/srhu50VWE9i

#News: With City Therapeutics we announced a new research collaboration to develop select novel RNAi-based therapies. Learn more about this announcement: bit.ly/3FtlSBA

Our Head of Development attended @FTPharma to discuss the role of AI strategy in advancing our late-stage pipeline. Joining industry leaders in these discussions is vital as we continue to explore the impact of AI in biopharma.